An Introduction to Heart Failure
Much progress has been made in the management of heart failure in patients with reduced ejection fraction (HFrEF) and the development of therapies for HF with preserved ejection fraction is ongoing. Promising new therapeutics in HF include a dual-acting angiotensin receptor-neprilysin inhibitor, soluble guanylate cyclase (sGC) stimulator and a cardiac myosin activator. It is hoped that gene therapy will be available for patients with HFrEF in the near future.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Heart Failure Content
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
The evolving management of chronic HF: Modulating vascular tone to improve outcomes for patients with worsening HFrEF
Join Dr Javed Butler as he presents the clinical features of worsening heart failure (HF) with reduced ejection fraction (HFrEF) and the latest data on pharmacological interventions to modulate vascular tone in HF.
- Describe the clinical features of worsening HFrEF and the characteristics of patients at risk of developing worsening disease
- Discuss the rationale for targeting the vascular endothelium and smooth muscle in HF and the available treatment options
- Summarize the most recent data on the modulation of vascular tone and its potential for the management of HFrEF
Explaining Sex Differences in Cardiac Resynchronisation Therapy Outcome
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):17-23 DOI: https://doi.org/10.17925/EJAE.2020.6.1.17
Over the past years, several reports have drawn attention to the need to consider sex-specific differences in cardiac resynchronisation therapy (CRT). Most importantly, there is growing concern on the underrepresentation of women in CRT landmark trials which laid the foundation for present guidelines. Patients with symptomatic heart failure, reduced left ventricular ejection fraction (LVEF) ≤35% […]
Joachim Ehrlich, ESC 2020 – Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation with Heart Failure
We caught up with Prof Joachim Ehrlich (Head of Cardiology and Electrophysiology, St Josefs-Hospital, Wiesbaden, Germany) on the recent studies in the use of pulmonary vein isolation in patients with atrial fibrillation and heart failure and the advantages of cryoballoon ablation compared with radiofrequency ablation. He also gave us an overview of their recent cohort […]
Quantification of Seasonal Variation in Daily Physical Activity in Individuals with Heart Failure and Implantable Cardioverter Defibrillator/Cardiac Resynchronisation Therapy Devices
Heart International. 2019;13(2):31–7
In individuals with heart failure (HF) who also have implanted cardioverter defibrillators and/or cardiac resynchronisation therapy (ICD/CRT) devices, low daily physical activity (PA) levels lead to increased risk of mortality, poor aerobic capacity and lower health-related quality of life.1 Improving daily PA in these individuals may, therefore, be an important clinical endpoint; however, designing interventional […]
Vishal Luther and Eileen Porter, HRC 2019 – Heart Failure and Atrial Fibrillation
We spoke to Dr Vishal Luther (Hammersmith Hospital, London, UK) and patient Eileen Porter at the 2019 Heart Rhythm Congress (HRC) in Birmingham, UK, about heart failure, atrial fibrillation and the patient experience. Speaker’s Disclosures: Vishal Luther has nothing to declare in relation to this video interview. touchCARDIO.com is an independent information resource supporting physicians, […]
Jean-François Obadia, ESC 2019 – Follow up from the MITRA-FR Trial
We spoke to Professor Jean-François Obadia (Civils Hospices of Lyon, Lyon, France) about the 2-year follow up from the MITRA-FR trial, and how he would interpret the differing results from recent studies into the efficacy of the MitraClip in patients with mitral regurgitation. Finally, he touches on which patients might be likely to benefit from […]
Benedikt Schrage, ESC 2019 – Implantable Devices and Heart Failure
We spoke to Dr Benedikt Schrage (Karolinska Institute, Stockholm, Sweden) for the key findings from his prospective study examining the association between the use of implantable cardioverter defibrillators and mortality in patients with heart failure. He also discusses how physicians might incorporate these findings into routine practice. Speaker’s Disclosures: Benedikt Schrage has received funding from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!